Psoriasis
📧 Sign up to get email alerts when something new happens for Psoriasis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2026-04-17FDA Approved: CALCIPOTRIENE — Supplemental Application (Glenmark Pharmaceuticals Inc.,USA)
FDA approved a supplemental application for CALCIPOTRIENE from Glenmark Pharmaceuticals, indicating an approved update to the existing ANDA …
-
EMA approval · 2026-04-16EMA Authorised: Steqeyma (ustekinumab) — Celltrion Healthcare Hungary Kft.
The EMA authorised Steqeyma (ustekinumab) by Celltrion Healthcare Hungary Kft for psoriasis, psoriatic arthritis, and Crohn's disease.
-
EMA approval · 2026-04-16EMA Authorised: Qoyvolma (ustekinumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Qoyvolma (ustekinumab) by Celltrion Healthcare Hungary Kft. for psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn…
-
EMA approval · 2026-04-14EMA Authorised: Spevigo (spesolimab) — LEO Pharma A/S
The EMA authorised Spevigo (spesolimab) by LEO Pharma A/S for psoriasis, with conditional approval.
-
EMA approval · 2026-03-30EMA Authorised: Imuldosa (ustekinumab) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Imuldosa (ustekinumab) from Accord Healthcare S.L.U. for Crohn's disease, psoriasis, and psoriatic …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-03-30EMA Authorised: Uzpruvo (ustekinumab) — Stada Arzneimittel AG
EMA authorised Uzpruvo (ustekinumab) for the treatment of psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.
-
EMA approval · 2026-03-20EMA Authorised: Apremilast Accord (apremilast) — Accord Healthcare S.L.U.
The EMA has authorised Accord Healthcare's apremilast product (Apremilast Accord) for psoriatic arthritis, psoriasis, Behçet's syndrome, and…
-
EMA approval · 2026-03-19EMA Authorised: Libmyris (adalimumab) — Stada Arzneimittel AG
EMA authorised Libmyris (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases, expanding treatment options in rheumatoid …
-
EMA approval · 2026-03-17EMA Authorised: Bimzelx (bimekizumab) — UCB Pharma S.A.
The EMA authorised Bimzelx (bimekizumab) from UCB Pharma S.A. for psoriasis, with a decision date of 28 April 2025.
-
EMA approval · 2026-03-04EMA Authorised: Otezla (apremilast) — Amgen Europe B.V.
The European Medicines Agency authorised Otezla (apremilast) for Behçet syndrome, in addition to its established uses in psoriatic arthritis…
-
EMA approval · 2026-02-24EMA Authorised: Fymskina (ustekinumab) — Formycon AG
The EMA authorised Fymskina, an ustekinumab biosimilar from Formycon AG, for Crohn's disease, psoriasis, and psoriatic arthritis.
-
EMA approval · 2026-02-19EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
The EMA authorised Hulio, a biosimilar of adalimumab, for multiple inflammatory indications including hidradenitis suppurativa, psoriasis, u…
-
EMA approval · 2026-02-18EMA Authorised: Wezenla (ustekinumab) — Amgen Technology (Ireland) UC
EU authorization for Wezenla, a ustekinumab product from Amgen Technology (Ireland) UC, indicated for psoriasis, psoriatic arthritis, and Cr…
-
EMA approval · 2026-02-17EMA Authorised: Inflectra (infliximab) — Pfizer Europe MA EEIG
EMA authorised Inflectra (infliximab) as a biosimilar to Remicade for multiple inflammatory diseases including rheumatoid and psoriatic arth…
-
EMA approval · 2026-02-16EMA Authorised: Yesintek (ustekinumab) — Biosimilar Collaborations Ireland Limited
The European Medicines Agency authorised Yesintek, a biosimilar of ustekinumab, for use in psoriasis, psoriatic arthritis, and Crohn's disea…
-
EMA approval · 2026-02-16EMA Authorised: Hefiya (adalimumab) — Sandoz GmbH
EMA authorised Hefiya, a biosimilar adalimumab from Sandoz GmbH, for multiple inflammatory conditions including ankylosing spondylitis, hidr…
-
EMA approval · 2026-02-05EMA Authorised: Yuflyma (adalimumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Yuflyma (adalimumab) as a biosimilar of adalimumab for several inflammatory and autoimmune diseases, including rheumatoid art…
-
EMA approval · 2026-01-28EMA Authorised: Hukyndra (adalimumab) — Stada Arzneimittel AG
EMA authorised Hukyndra (adalimumab) from Stada Arzneimittel AG for multiple inflammatory diseases, including rheumatoid arthritis, psoriati…
-
FDA approval · 2026-01-21FDA Approved: CYCLOSPORINE — Original Application (Upsher-Smith Laboratories, LLC)
FDA approved Upsher-Smith's original ANDA for generic cyclosporine.
-
EMA approval · 2026-01-19EMA Authorised: Skyrizi (risankizumab) — AbbVie Deutschland GmbH & Co. KG
The EMA authorised Skyrizi (risankizumab) for multiple indications. This expands its approved uses to psoriasis, psoriatic arthritis, ulcera…
-
EMA approval · 2026-01-09EMA Authorised: Usymro (ustekinumab) — Gedeon Richter Plc.
EMA authorised Usymro (ustekinumab) by Gedeon Richter for Crohn's disease, psoriasis, and psoriatic arthritis.
-
EMA approval · 2025-12-18EMA Authorised: Cosentyx (secukinumab) — Novartis Europharm Limited
The EMA authorised Cosentyx (secukinumab) for psoriatic arthritis, psoriasis, and ankylosing spondylitis.
-
FDA approval · 2025-12-16FDA Approved: BECLOMETHASONE DIPROPIONATE — Original Application (Amneal Pharmaceuticals NY LLC)
The FDA approved Amneal Pharmaceuticals NY LLC's Beclomethasone Dipropionate as an original-application generic medication, a topical cortic…
-
EMA approval · 2025-12-15EMA Authorised: Remicade (infliximab) — Janssen Cilag International NV
The EMA has authorised Remicade (infliximab) for multiple inflammatory diseases under Janssen Cilag International NV as the marketing author…
-
EMA approval · 2025-12-11EMA Authorised: Hyrimoz (adalimumab) — Sandoz GmbH
EMA authorised Hyrimoz (adalimumab) by Sandoz GmbH as a biosimilar to Humira for multiple inflammatory diseases, including rheumatoid arthri…